Cell Type Atlas

📖 Wiki Page

cell2252 wordssynced 2026-04-02

Cell Type Atlas

Overview

...

Cell Type Atlas

Overview

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Cell Type Atlas</th>
</tr>
<tr>
<td class="label">Region</td>
<td>Neuron Type</td>
</tr>
<tr>
<td class="label">SNpc</td>
<td>A9 neurons</td>
</tr>
<tr>
<td class="label">VTA</td>
<td>A10 neurons</td>
</tr>
<tr>
<td class="label">retrorubral</td>
<td>A8 neurons</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Corticospinal</td>
<td>Layer V motor cortex</td>
</tr>
<tr>
<td class="label">Corticobrainstem</td>
<td>Motor cortex</td>
</tr>
<tr>
<td class="label">Spinal alpha</td>
<td>Ventral horn</td>
</tr>
<tr>
<td class="label">Spinal gamma</td>
<td>Ventral horn</td>
</tr>
<tr>
<td class="label">Interneuron Type</td>
<td>Markers</td>
</tr>
<tr>
<td class="label">Parvalbumin (PV)</td>
<td>PV, C氨酸激酶</td>
</tr>
<tr>
<td class="label">Somatostatin (SST)</td>
<td>SST, NOS</td>
</tr>
<tr>
<td class="label">VIP</td>
<td>VIP, 5-HT3aR</td>
</tr>
<tr>
<td class="label">Chandelier</td>
<td>C氨酸激酶</td>
</tr>
<tr>
<td class="label">Neurogliaform</td>
<td>C氨酸激酶, NPY</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Nucleus</td>
</tr>
<tr>
<td class="label">Basal forebrain</td>
<td>Nucleus basalis</td>
</tr>
<tr>
<td class="label">Basal forebrain</td>
<td>Medial septum</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Pedunculopontine</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Laterodorsal tegmentum</td>
</tr>
<tr>
<td class="label">State</td>
<td>Markers</td>
</tr>
<tr>
<td class="label">Resting</td>
<td>Iba1+, CX3CR1high</td>
</tr>
<tr>
<td class="label">Disease-associated (DAM)</td>
<td>TREM2+, ApoE+</td>
</tr>
<tr>
<td class="label">Neurotoxic (M1)</td>
<td>iNOS+, TNF-α+</td>
</tr>
<tr>
<td class="label">Neuroprotective (M2)</td>
<td>Arg1+, CD206+</td>
</tr>
<tr>
<td class="label">Dystrophic</td>
<td>CD68high, C4+</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Markers</td>
</tr>
<tr>
<td class="label">Protoplasmic</td>
<td>GFAP+, S100β+</td>
</tr>
<tr>
<td class="label">Fibrous</td>
<td>GFAP+</td>
</tr>
<tr>
<td class="label">Radial</td>
<td>GFAP+, BLBP+</td>
</tr>
<tr>
<td class="label">Bergmann</td>
<td>GFAP+</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Vulnerability</td>
</tr>
<tr>
<td class="label">Cholinergic neurons (basal forebrain)</td>
<td>Severe</td>
</tr>
<tr>
<td class="label">Pyramidal neurons (cortex)</td>
<td>Severe</td>
</tr>
<tr>
<td class="label">GABAergic interneurons</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>Chronic activation</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>Reactive</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Vulnerability</td>
</tr>
<tr>
<td class="label">Dopaminergic neurons (SNpc)</td>
<td>Severe</td>
</tr>
<tr>
<td class="label">Noradrenergic neurons (LC)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Serotonergic neurons (raphe)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cholinergic neurons</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>Reactive</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Vulnerability</td>
</tr>
<tr>
<td class="label">Motor neurons (upper/lower)</td>
<td>Severe</td>
</tr>
<tr>
<td class="label">Cortical pyramidal neurons</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">GABAergic interneurons</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>Toxic phenotype</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>Activated</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Vulnerability</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Severe</td>
</tr>
<tr>
<td class="label">Dopaminergic neurons</td>
<td>Severe</td>
</tr>
<tr>
<td class="label">Autonomic neurons</td>
<td>Severe</td>
</tr>
<tr>
<td class="label">Cholinergic neurons</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Vulnerability</td>
</tr>
<tr>
<td class="label">Medium spiny neurons</td>
<td>Severe</td>
</tr>
<tr>
<td class="label">Cortical pyramidal neurons</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Moderate</td>
</tr>
</table>

The brain contains a remarkable diversity of cell types, each with specialized functions essential for neural circuit operation and overall brain health. Neurodegenerative diseases selectively target specific neuronal populations and glial cells, leading to characteristic patterns of pathology and clinical symptoms. Understanding which cell types are vulnerable in each disease, and why, is fundamental to developing effective therapeutic interventions[@bjorklund2020].

This comprehensive atlas provides detailed information about each major brain cell type implicated in neurodegenerative diseases, including their normal functions, vulnerability mechanisms, and roles in disease pathogenesis.

Neuronal Cell Types

Neurons are the primary information-processing cells of the brain. Different neuronal populations exhibit selective vulnerability to different neurodegenerative processes.

Dopaminergic Neurons

Location and Function:
Dopaminergic neurons are primarily located in the substantia nigra pars compacta (SNpc), ventral tegmental area (VTA), and retrorubral area. These neurons synthesize and release dopamine as their primary neurotransmitter and play essential roles in motor control, reward processing, motivation, and cognitive function[@kirmse2019].

Subtypes:

Molecular Markers:

tyrosine hydroxylase (TH): Rate-limiting enzyme in dopamine synthesis
AADC: Aromatic L-amino acid decarboxylase
DAT: Dopamine transporter
VMAT2: Vesicular monoamine transporter 2
Pitx3: Transcription factor for survival

Vulnerability Mechanisms:

Oxidative stress: High metabolic demand and dopamine oxidation
Mitochondrial dysfunction: Complex I deficiency
Calcium dysregulation: Pacemaker activity increases calcium influx
Neuroinflammation: Microglial activation
Alpha-synuclein pathology: Lewy body formation[@sohrabi2015]

Disease Involvement:

Parkinson's Disease:
Dopaminergic neuron loss in the SNpc is the hallmark pathological feature of PD, causing the characteristic motor symptoms of tremor, bradykinesia, and rigidity. Approximately 70% of SNpc neurons are lost before motor symptoms appear. The vulnerability of these neurons relates to their unique physiology: they are autonomous pacemakers with low mitochondrial reserve and high iron content[@smith2020].

Multiple System Atrophy:
Both SNpc and VTA neurons are affected, contributing to parkinsonian and autonomic symptoms. The pattern of loss differs from PD, with earlier autonomic involvement.

Progressive Supranuclear Palsy:
Dopaminergic neurons are affected as part of the broader subcortical pathology, though motor symptoms may be less prominent than in PD.

Motor Neurons

Location and Function:
Motor neurons are located in the motor cortex (upper motor neurons), brainstem (cranial nerve nuclei), and spinal cord (lower motor neurons). They control voluntary muscle movement and are essential for all motor actions[@boillee2006].

Subtypes:

Molecular Markers:

SOD1: Superoxide dismutase 1 (mutations cause familial ALS)
TDP-43: TAR DNA-binding protein 43 (aggregates in ALS)
FUS: Fused in sarcoma (ALS mutations)
C9orf72: Hexanucleotide repeat expansions in ALS
ChAT: Choline acetyltransferase

Vulnerability Mechanisms:

Amyotrophic Lateral Sclerosis (ALS):

Non-cell autonomous toxicity: Astrocyte and microglia contribute
Excitotoxicity: Glutamate-induced calcium overload
Mitochondrial dysfunction: Energy failure
Protein aggregation: TDP-43, SOD1, FUS inclusions
Axonal transport defects: Impaired cargo delivery
Oxidative stress: Reactive oxygen species accumulation

Spinal Muscular Atrophy (SMA):

SMN protein deficiency: Splicing defects
Motor neuron-specific vulnerability: Due to long axons
Synaptic dysfunction: Neuromuscular junction denervation

Kennedy's Disease (SBMA):

Androgen receptor polyglutamine expansions: Toxic gain-of-function
Lower motor neuron specificity: Hormonal factors

Hereditary Spastic Paraplegia:

Corticospinal tract degeneration: Upper motor neuron loss
Axonal transport defects: SPG proteins

GABAergic Neurons

Location and Function:
GABAergic neurons are inhibitory neurons that use gamma-aminobutyric acid (GABA) as their neurotransmitter. They are critical for maintaining the balance between excitation and inhibition in neural circuits, preventing hyperexcitability, and modulating network oscillations[@schoch2016].

Major Subtypes:

Vulnerability in Disease:

Alzheimer's Disease:

PV interneuron dysfunction contributes to network hyperexcitability
Reduced inhibition leads to epileptiform activity
SST neuron loss impairs dendritic inhibition
Gamma oscillation disruption affects cognition

Parkinson's Disease:

Altered GABAergic signaling in basal ganglia
Excessive inhibition of movement-promoting pathways
Interneuron loss in cortex contributes to cognitive deficits

Huntington's Disease:

GABAergic neuron loss in striatum (medium spiny neurons)
Circuit disinhibition leads to involuntary movements
Cortical interneuron dysfunction contributes to cognitive decline

Epilepsy:

Often co-occurs with neurodegenerative diseases
Loss of inhibitory control
Circuit reorganization leads to hyperexcitability

Cholinergic Neurons

Location and Function:
Cholinergic neurons use acetylcholine as their neurotransmitter and play critical roles in attention, memory, learning, and arousal. Major populations include basal forebrain cholinergic neurons and brainstem cholinergic nuclei[@masliah2010].

Subtypes:

Molecular Markers:

ChAT: Choline acetyltransferase
AChE: Acetylcholinesterase
VACht: Vesicular acetylcholine transporter
p75NTR: Low-affinity NGF receptor
TrkA: High-affinity NGF receptor

Disease Involvement:

Alzheimer's Disease:

Early and prominent cholinergic neuron loss
Basal forebrain neurons particularly vulnerable
Correlates with memory and attention deficits
Basis for acetylcholinesterase inhibitor therapy

Parkinson's Disease:

Cholinergic dysfunction contributes to cognitive impairment
Pedunculopontine nucleus degeneration leads to gait dysfunction
Cortical cholinergic denervation

Dementia with Lewy Bodies:

Prominent cholinergic deficits
Often more severe than in AD
Contributes to attentional fluctuations

Serotonergic Neurons

Location and Function:
Serotonergic neurons are primarily located in the raphe nuclei of the brainstem and project widely throughout the brain. They modulate mood, sleep, appetite, and pain processing.

Molecular Markers:

Tryptophan hydroxylase 2 (TPH2): Serotonin synthesis
Serotonin transporter (SERT): Reuptake
VMAT2: Vesicular transport

Disease Involvement:

Parkinson's Disease: Raphe nuclei affected
Alzheimer's Disease: Serotonergic dysfunction
Depression: Co-occurs with neurodegeneration

Noradrenergic Neurons

Location and Function:
Noradrenergic neurons are primarily located in the locus coeruleus and project throughout the brain. They are critical for arousal, attention, and stress responses.

Disease Involvement:

Alzheimer's Disease: Early locus coeruleus involvement
Parkinson's Disease: Noradrenergic dysfunction
Multiple System Atrophy: Severe LC degeneration

Glial Cell Types

Glial cells were once thought to be mere support cells but are now recognized as active participants in neural circuit function and major contributors to neurodegenerative disease pathogenesis[@bhardwaj2022].

Microglia

Function:
Microglia are the resident immune cells of the central nervous system. They survey the brain environment, respond to pathogens and injury, phagocytose debris, and modulate synaptic function. In the healthy brain, they maintain tissue homeostasis[@guttenplan2020].

Molecular Markers:

Iba1: Ionized calcium-binding adapter molecule 1
CD68: Lysosomal marker for activated microglia
CD14: Pattern recognition receptor
TREM2: Triggering receptor on myeloid cells 2
CX3CR1: Fractalkine receptor

Activation States:

Role in Neurodegenerative Diseases:

Alzheimer's Disease:

TREM2 variants: Risk factor affecting phagocytosis
DAM formation: Aβ clearance attempt
Chronic inflammation: Cytokine release damages neurons
Synaptic pruning: Excessive elimination of synapses
Neurotoxic reactive astrocytes: Induced by microglia[@liddelow2017]

Parkinson's Disease:

α-Synuclein recognition: Patter recognition receptors
Pro-inflammatory activation: TNF-α, IL-1β, IL-6
NLRP3 inflammasome: Inflammatory cascade
Mitochondrial antigens: Foreign-like immune response

Amyotrophic Lateral Sclerosis:

Non-cell autonomous toxicity: Kill motor neurons
SOD1 propagation: Intercellular spread
Pro-inflammatory cytokines: Excitotoxicity
TREM2 involvement: Altered phagocytosis[@rizzuto2019]

Astrocytes

Function:
Astrocytes are the most abundant glial cell type in the brain. They provide metabolic support to neurons, regulate extracellular ion and neurotransmitter levels, maintain the blood-brain barrier, and participate in synaptic transmission and plasticity[@barres2008].

Subtypes:

Molecular Markers:

GFAP: Glial fibrillary acidic protein
S100β: Calcium-binding protein
AQP4: Water channel
GLT-1: Glutamate transporter
Aldh1l1: Metabolic enzyme

Disease Involvement:

Alzheimer's Disease:

Reactive astrogliosis: Aβ and tau induce proliferation
Neurotoxic A1 phenotype: Induced by microglia
Glutamate dysregulation: Impaired uptake
Metabolic dysfunction: Energy failure
Blood-brain barrier disruption[@suarez-calvet2020]

Parkinson's Disease:

DOPA toxicity: Astrocyte metabolism of dopamine
Neuroinflammation: Pro-inflammatory activation
α-Synuclein clearance: Attempted phagocytosis
Iron accumulation: Transferrin dysregulation

Amyotrophic Lateral Sclerosis:

Non-cell autonomous toxicity: Release toxic factors
Excitotoxicity: Impaired glutamate clearance
SOD1 expression: Mutant SOD1 in astrocytes
TDP-43 pathology: Aggregates in astrocytes[@henkel2009]

Huntington's Disease:

Metabolic dysfunction: Energy failure
Glutamate toxicity: Impaired uptake
Loss of trophic support: Reduced BDNF

Multiple Sclerosis:

Astrocyte loss: In lesions
Reparative gliosis: Scar formation
Dysfunctional scar: Impaired repair

Oligodendrocytes

Function:
Oligodendrocytes are responsible for producing and maintaining the myelin sheath that insulates axons, enabling rapid saltatory conduction of action potentials. Each oligodendrocyte can myelinate multiple axons[@silke2015].

Molecular Markers:

MBP: Myelin basic protein
PLP: Proteolipid protein
Olig2: Transcription factor
NG2: Chondroitin sulfate proteoglycan
CC1: Oligodendrocyte marker

Vulnerability Mechanisms:

Metabolic dependence: High energy demands
Iron accumulation: Age-related deposition
Remote injury effects: Wallerian degeneration
Autoimmune attack: In MS

Disease Involvement:

Multiple Sclerosis:

Primary target: Immune-mediated destruction
Demyelination: Conduction block
Remyelination failure: Precursor exhaustion
Axonal loss: Secondary to demyelination

Alzheimer's Disease:

White matter degeneration: Secondary to neuronal loss
Myelin breakdown: Amyloid effect
Oligodendrocyte loss: In affected regions

Parkinson's Disease:

White matter changes: Secondary to neurodegeneration
Reduced myelin: Functional significance unclear

Huntington's Disease:

White matter abnormalities: Widespread
Oligodendrocyte dysfunction: Mutant huntingtin

Amyotrophic Lateral Sclerosis:

White matter degeneration: Shown on MRI[@agosta2009]
Secondary involvement: As motor neurons die

NG2 Glia (Oligodendrocyte Precursor Cells)

Function:
NG2-expressing glia are proliferative progenitor cells that can differentiate into oligodendrocytes. They also form synaptic contacts with neurons and may have additional functions in neural circuits.

Molecular Markers:

NG2 (CSPG4): Chondroitin sulfate proteoglycan
PDGFRα: Platelet-derived growth factor receptor alpha
Olig2: Transcription factor

Disease Involvement:

Failed remyelination: In MS and other conditions
Proliferation in response to injury: Potential therapy target
Neuronal dysfunction: Altered neuron-glia signaling

Summary: Cell Type Vulnerability by Disease

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Multiple System Atrophy

Huntington's Disease

Therapeutic Implications

Cell-Type Specific Approaches

Neuronal Protection:

Neurotrophic factors (BDNF, GDNF)
Antioxidants targeting specific populations
Calcium channel modulators
Anti-excitotoxicity agents

Glial Modulation:

Anti-inflammatory therapies
TREM2-targeted interventions
Astrocyte metabolic support
Remyelination promotion

Cell Replacement:

Stem cell-derived neurons
Gene therapy for specific populations
Supportive glial transplantation

Biomarker Development

Cell-type-specific biomarkers are being developed to:

Detect disease progression
Monitor treatment response
Identify specific cell types affected
Enable early diagnosis

Brain Atlas Resources

[Allen Human Brain Atlas](https://human.brain-map.org/) — gene expression data
[BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
[Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — comprehensive cell type taxonomy
[SEA-AD](/projects/sea-ad) — Alzheimer's disease cell atlas

References

[Björklund & Lindvall, Cell therapy (2020)](https://doi.org/10.1038/s41583-020-0278-4)

[Kirmse et al., Neuronal vulnerability (2019)](https://doi.org/10.1093/brain/awz192)

[Sohrabi et al., Gene expression in AD (2015)](https://doi.org/10.1038/nn.4028)

[Bhardwaj et al., Glial cells (2022)](https://doi.org/10.1016/j.pneurobio.2022.102357)

[Guttenplan et al., Neurotoxic microglia (2020)](https://doi.org/10.1038/s41583-020-0309-z)

[Liddelow et al., Reactive astrocytes (2017)](https://doi.org/10.1038/nature21029)

[Peelaerts et al., α-Synuclein (2015)](https://doi.org/10.3233/JPD-150543)

[Bates et al., Huntington disease (2013)](https://doi.org/10.1038/nrg3470)

[Boillee et al., ALS mechanisms (2006)](https://doi.org/10.1038/nrn1873)

[Silke et al., Oligodendrocyte death (2015)](https://doi.org/10.1002/glia.22940)

[Rizzuto et al., Microglia in AD (2019)](https://doi.org/10.1038/s41582-019-0217-1)

[Suarez-Calvet et al., TREM2 in AD (2020)](https://doi.org/10.15252/emmm.201911610)

[Henkel et al., Astrocytes in ALS (2009)](https://doi.org/10.1016/j.expneurol.2008.12.023)

[Barres, Mystery of glia (2008)](https://doi.org/10.1038/nature07385)

[Taylor et al., Decoding ALS (2013)](https://doi.org/10.1038/nature12289)

[Smith et al., PD neuronal vulnerability (2020)](https://doi.org/10.1038/s41582-020-0339-y)

[Schoch et al., Excitotoxicity (2016)](https://doi.org/10.1016/j.nbd.2016.01.006)

[Castriota et al., Dystrophic microglia (2020)](https://doi.org/10.1186/s40478-020-00977-7)

[Masliah et al., Synaptic dysfunction (2010)](https://doi.org/10.1038/nrneurol.2010.27)

[Rae et al., Astrocyte metabolism (2011)](https://doi.org/10.1007/s11064-011-0626-8)

[Chrousos, Stress and neurodegeneration (1992)](https://doi.org/10.1111/j.1749-6632.1992.tb27229.x)

[Polireddy et al., ATP release (2012)](https://doi.org/10.1007/s11302-012-9308-5)

[Agosta et al., White matter damage (2009)](https://doi.org/10.1212/WNL.0b013e3181c1ded1)

📖 View canonical wiki page →

Cell Type Atlas

Cell Type Atlas

Overview

Cell Type Atlas

Overview

Neuronal Cell Types

Dopaminergic Neurons

Motor Neurons

GABAergic Neurons

Cholinergic Neurons

Serotonergic Neurons

Noradrenergic Neurons

Glial Cell Types

Microglia

Astrocytes

Oligodendrocytes

NG2 Glia (Oligodendrocyte Precursor Cells)

Summary: Cell Type Vulnerability by Disease

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Multiple System Atrophy

Huntington's Disease

Therapeutic Implications

Cell-Type Specific Approaches

Biomarker Development

See Also

Brain Atlas Resources

References